QTc Prolongation in Pediatric Patients with Diabetic Ketoacidosis

Michelle M Perez1, Shivanand Medar2, Leanne Quigley3

  • 1Division of Pediatric Critical Care, Children's Hospital at Montefiore, Bronx, NY.

The Journal of Pediatrics
|September 5, 2020
PubMed

Insights

Diabetic ketoacidosis (DKA) in children is linked to prolonged QTc intervals, with severity correlating to the degree of prolongation. This finding highlights potential cardiac risks in pediatric DKA patients.

Area of Science:

  • Pediatric Cardiology
  • Endocrinology
  • Clinical Electrophysiology

Background:

  • Diabetic ketoacidosis (DKA) is a serious complication of diabetes mellitus.
  • QTc interval prolongation is a risk factor for cardiac arrhythmias.

Purpose of the Study:

  • To investigate the association between DKA and QTc interval prolongation in pediatric patients.
  • To assess the correlation between DKA severity and QTc prolongation.

Main Methods:

  • Retrospective observational study of 96 pediatric patients admitted with DKA.
  • Electrocardiograms (ECGs) were analyzed for QTc interval using Bazett's formula.
  • DKA severity was classified based on pH levels; patients on QTc-prolonging medications were excluded.

Main Results:

  • Mean QTc interval in DKA patients was 454 ± 32 msec.
  • Significant differences in QTc intervals were observed across DKA severity groups (P = .05).
  • Higher anion gaps were significantly associated with longer QTc intervals (r = 0.21, P = .04).

Conclusions:

  • Thirty-one percent of pediatric DKA patients exhibited QTc prolongation.
  • DKA severity and worsening acidosis are associated with increased QTc prolongation.
  • Further research is needed to determine the clinical implications of these findings.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
145
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
499
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
168
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.6K